Peter Brauchli

2.0k total citations
43 papers, 1.5k citations indexed

About

Peter Brauchli is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Peter Brauchli has authored 43 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Peter Brauchli's work include Gastric Cancer Management and Outcomes (9 papers), Cancer Treatment and Pharmacology (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Peter Brauchli is often cited by papers focused on Gastric Cancer Management and Outcomes (9 papers), Cancer Treatment and Pharmacology (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Peter Brauchli collaborates with scholars based in Switzerland, Germany and France. Peter Brauchli's co-authors include Hans Zeier, Helen I. Joller‐Jemelka, Roger von Moos, Bernhard C. Pestalozzi, Richard Herrmann, Daniel Dietrich, Piercarlo Saletti, Markus Borner, Dirk Klingbiel and Thomas Ruhstaller and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Surgery.

In The Last Decade

Peter Brauchli

41 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Brauchli Switzerland	21	760	467	314	183	129	43	1.5k
Christoph Schulz Germany	25	744 1.0×	403 0.9×	644 2.1×	253 1.4×	143 1.1×	78	1.9k
Seth Thompson United States	19	473 0.6×	324 0.7×	315 1.0×	305 1.7×	218 1.7×	27	1.8k
André L. Mihaljević Germany	29	1.3k 1.7×	808 1.7×	1.3k 4.1×	189 1.0×	225 1.7×	113	2.5k
Stewart W. McCallum United States	22	170 0.2×	270 0.6×	370 1.2×	367 2.0×	50 0.4×	57	1.4k
Michelle Harrison Australia	23	621 0.8×	233 0.5×	164 0.5×	255 1.4×	145 1.1×	88	1.4k
Hiroaki Kato Japan	20	325 0.4×	447 1.0×	421 1.3×	158 0.9×	53 0.4×	109	1.9k
Matthew Dixon United States	14	393 0.5×	138 0.3×	508 1.6×	135 0.7×	40 0.3×	26	1.4k
Jennifer Carter United Kingdom	23	294 0.4×	355 0.8×	145 0.5×	319 1.7×	128 1.0×	57	1.4k
Shin‐Liang Pan Taiwan	23	289 0.4×	226 0.5×	318 1.0×	153 0.8×	132 1.0×	68	1.5k
Tomoko Yamazaki Japan	20	430 0.6×	187 0.4×	269 0.9×	305 1.7×	81 0.6×	75	1.4k

Countries citing papers authored by Peter Brauchli

Since Specialization

Citations

This map shows the geographic impact of Peter Brauchli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Brauchli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Brauchli more than expected).

Fields of papers citing papers by Peter Brauchli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Brauchli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Brauchli. The network helps show where Peter Brauchli may publish in the future.

Co-authorship network of co-authors of Peter Brauchli

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Brauchli. A scholar is included among the top collaborators of Peter Brauchli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Brauchli. Peter Brauchli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tejpar, Sabine, Pu Yan, Hubert Piessevaux, et al.. (2018). Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. European Journal of Cancer. 99. 66–77. 19 indexed citations

Herrmann, Evelyn, M. Sassowsky, Jeroen Buijsen, et al.. (2017). External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26. Radiation Oncology. 12(1). 12–12. 7 indexed citations

Ruhstaller, Thomas, Peter Thuss‐Patience, Stefanie Hayoz, et al.. (2017). Intergroup phase III trial of neo-adjuvant chemotherapy, followed by chemoradiation and surgery with and without cetuximab in locally advanced esophageal carcinoma: First results from the SAKK 75/08 trial.. Journal of Clinical Oncology. 35(15_suppl). 4019–4019. 4 indexed citations

Maurer, Christoph A., Daniel Dietrich, Martin K. Schilling, et al.. (2016). Prospective multicenter registration study of colorectal cancer: significant variations in radicality and oncosurgical quality—Swiss Group for Clinical Cancer Research Protocol SAKK 40/00. International Journal of Colorectal Disease. 32(1). 57–74. 6 indexed citations

Gargiulo, Piera, Chiara Della Pepa, Simona Berardi, et al.. (2016). Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?. Cancer Treatment Reviews. 48. 61–68. 93 indexed citations

Koeberle, Dieter, Daniel Betticher, Roger von Moos, et al.. (2015). Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Annals of Oncology. 26(4). 709–714. 92 indexed citations

Joerger, Markus, Florent Baty, Martin Früh, et al.. (2014). Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer. 85(2). 306–313. 38 indexed citations

Passweg, Jakob, Thomas Pabst, Sabine Blum, et al.. (2013). Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07). Leukemia & lymphoma. 55(1). 87–91. 22 indexed citations

Renner, Christoph, Pier Luigi Zinzani, Rémy Gressin, et al.. (2012). A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica. 97(7). 1085–1091. 77 indexed citations

10.

Cathomas, Richard, Christian Rothermundt, Dirk Klingbiel, et al.. (2012). Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07). Clinical Cancer Research. 18(21). 6049–6057. 40 indexed citations

11.

Zappa, Francesco, Daniel Betticher, Roger von Moos, et al.. (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). Lung Cancer. 78(3). 239–244. 27 indexed citations

12.

Zaman, Khalil, Beat Thürlimann, Jens Huober, et al.. (2011). Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Annals of Oncology. 23(6). 1474–1481. 32 indexed citations

13.

Leupin, Nicolas, Jan C. Schuller, Max Solenthaler, et al.. (2010). Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02). Leukemia & lymphoma. 51(4). 613–619. 6 indexed citations

14.

Jöst, Christian, Janek Binek, Jan C. Schuller, et al.. (2010). Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02). Gastrointestinal Endoscopy. 71(7). 1114–1121. 28 indexed citations

15.

Matter‐Walstra, Klazien, Konstantin J. Dedes, Matthias Schwenkglenks, et al.. (2010). Trastuzumab beyond progression: a cost-utility analysis. Annals of Oncology. 21(11). 2161–2168. 23 indexed citations

16.

Dedes, Konstantin J., Klazien Matter‐Walstra, Matthias Schwenkglenks, et al.. (2009). Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation. European Journal of Cancer. 45(8). 1397–1406. 56 indexed citations

17.

Schuller, Jan C., Michael Mayer, Doris Lanz, et al.. (2009). A novel diagram and complement to the CONSORT chart for presenting multimodal clinical trials. Contemporary Clinical Trials. 30(3). 201–204. 2 indexed citations

18.

Uhlmann, Catrina, Pierluigi Ballabeni, Peter Brauchli, et al.. (2004). Capecitabine with Weekly Paclitaxel for Advanced Breast Cancer: A Phase I Dose-Finding Trial. Oncology. 67(2). 117–122. 15 indexed citations

19.

Brauchli, Peter, et al.. (1996). [Use of complimentary medical therapies in HIV/AIDS in Switzerland].. PubMed. 126(30). 1297–305. 3 indexed citations

20.

Brauchli, Peter, et al.. (1995). Electrocortical and Autonomic Alteration by Administration of a Pleasant and an Unpleasant Odor. Chemical Senses. 20(5). 505–515. 134 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact